Reviewing Biotricity (NASDAQ:BTCY) and DexCom (NASDAQ:DXCM)

DexCom (NASDAQ:DXCM) and Biotricity (NASDAQ:BTCY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, earnings, dividends and risk.

Profitability

This table compares DexCom and Biotricity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DexCom	14.29%	30.14%	10.11%
Biotricity	-80.42%	N/A	-188.47%

Risk and Volatility

DexCom has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for DexCom and Biotricity, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	0	3	13	2	2.94
Biotricity	0	1	0	0	2.00

DexCom currently has a consensus price target of $99.82, indicating a potential upside of 28.24%. Given DexCom’s stronger consensus rating and higher probable upside, research analysts plainly believe DexCom is more favorable than Biotricity.

Institutional & Insider Ownership

97.8% of DexCom shares are owned by institutional investors. Comparatively, 3.9% of Biotricity shares are owned by institutional investors. 0.3% of DexCom shares are owned by company insiders. Comparatively, 10.1% of Biotricity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares DexCom and Biotricity”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.03 billion	7.54	$576.20 million	$1.43	54.43
Biotricity	$12.06 million	1.13	-$14.09 million	($1.08)	-0.51

DexCom has higher revenue and earnings than Biotricity. Biotricity is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Summary

DexCom beats Biotricity on 13 of the 15 factors compared between the two stocks.

About DexCom

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.